Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders

Area of Science:

• Endocrinology and Metabolism
• Pharmacology
• Neuroscience

Background:

• Glucose-dependent insulinotropic polypeptide (GIP) was historically overlooked due to perceived limitations in type 2 diabetes (T2DM) treatment.
• Previous understanding of GIP's role in glucose homeostasis was incomplete, particularly regarding glucagon secretion and inter-islet cell communication.
• Translational challenges between rodent models and human physiology previously hindered GIP therapeutic development.

Purpose of the Study:

• To review the renewed scientific interest in GIP, driven by a deeper understanding of its diverse physiological actions.
• To synthesize current evidence on GIP's pleiotropic effects beyond the pancreas, including metabolic, bone, cardiovascular, and neuroprotective roles.
• To highlight the therapeutic potential of GIP-based therapies, especially in combination with other agents like GLP-1 agonists, for metabolic and neurodegenerative diseases.

Main Methods:

• Literature review synthesizing preclinical and clinical studies on GIP.
• Analysis of GIP's molecular mechanisms and physiological effects across various tissues.
• Comparison of GIP-based therapies with existing treatments, including GLP-1 receptor agonists and dual agonists like Tirzepatide.

Main Results:

• GIP exhibits complex roles in glucose homeostasis, including glucose-dependent insulin and paradoxical hyperglycemia-induced glucagon secretion, potentially enhancing insulin release via paracrine signaling.
• GIP demonstrates pleiotropic effects: promoting lipid storage, reducing ectopic fat, modulating bone, influencing cardiovascular lipids, and offering neuroprotection.
• GIP-based therapies show promise in improving glycemic control, reducing obesity-related inflammation, enhancing insulin sensitivity, and ameliorating neurodegenerative pathology.
• Dual GIP/GLP-1 receptor agonists like Tirzepatide show superior efficacy over selective GLP-1 agonists in reducing HbA1c and body weight.

Conclusions:

• GIP has evolved from a challenging therapeutic target to a multifaceted agent with significant potential for metabolic and neurodegenerative disorders.
• GIP's synergistic effects with GLP-1, as seen with Tirzepatide, offer enhanced therapeutic benefits.
• Further research is needed to elucidate GIP's tissue-specific signaling and optimize multi-agonist therapies for complex diseases.